Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 13, 2000

View Archived Issues

KRP-297 improves glucose uptake in skeletal muscle in insulin-resistant mice

Selective factor Xa inhibitor assessed in experimental model of tumor-induced DIC

Abgenix and Elan enter antibody collaboration for neurological diseases

IL-1/TNF-alpha suppressant ameliorates intestinal ischemia-reperfusion injury in dogs

PathoGenesis and Chiron form antibiotic collaboration

Hemosol completes phase II trial of Hemolink in CABG patients

Myriad Genetics and Roche to collaborate on cardiovascular drug discovery

Alexion files IND for C5 inhibitor trial in psoriasis patients

FDA to review Aptosyn NDA without ODAC input

Corixa to commence phase II trials of PVAC for treatment of psoriasis

Synsorb Cd receives fast track designation from FDA for CDAD treatment

AHP dedicates substantial effort to discovery of PTPase inhibitors

Knoll compounds with nanomolar affinity for 5-HT, dopamine and adrenergic receptor subtypes

Preparation, biological activity and use of neurokinin antagonists reported by Sanofi-Synthelabo

Allelix (now NPS Pharmaceuticals) develops novel pharmaceuticals for neurological and CNS disorders

Sanofi-Synthelabo presents new muscle relaxant

Agents for cough in development at Nortran as alternatives to codeine

Development of nucleoside RT inhibitor effective against resistant HIV strains

DuPont's new expanded-spectrum NNRTIs advance towards clinical trials

Respiratory disease collaboration ended by mutual agreement by Millennium and AstraZeneca

Further investigations on the antiinflammatory effect of rutaecarpine

Micrologix successfully completes phase II trials of novel peptide antibiotic

Icos updates clinical program at healthcare conference

Orally active neurotrophic agent SR-57746A may act by inhibiting tyrosine kinase

Cephalon's CEP-701 enters phase II trials in prostate cancer

ImClone Systems achieves milestone in IMC-C225 collaboration with Merck KGaA

TKT completes pivotal phase III studies of GA-EPO as treatment of renal failure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...